Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting Fas in osteoresorptive disorders.

Kovacic N, Grcevic D, Katavic V, Lukic IK, Marusic A.

Expert Opin Ther Targets. 2010 Oct;14(10):1121-34. doi: 10.1517/14728222.2010.522347. Review.

2.

Fas receptor is required for estrogen deficiency-induced bone loss in mice.

Kovacic N, Grcevic D, Katavic V, Lukic IK, Grubisic V, Mihovilovic K, Cvija H, Croucher PI, Marusic A.

Lab Invest. 2010 Mar;90(3):402-13. doi: 10.1038/labinvest.2009.144. Epub 2010 Jan 18.

3.

The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis.

Kovacić N, Lukić IK, Grcević D, Katavić V, Croucher P, Marusić A.

J Immunol. 2007 Mar 15;178(6):3379-89.

4.

Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass.

Wang L, Liu S, Zhao Y, Liu D, Liu Y, Chen C, Karray S, Shi S, Jin Y.

Cell Death Differ. 2015 Oct;22(10):1654-64. doi: 10.1038/cdd.2015.14. Epub 2015 Mar 6.

5.

Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.

Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M.

EMBO J. 2008 Feb 6;27(3):535-45. doi: 10.1038/sj.emboj.7601984. Epub 2008 Jan 24.

6.

ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis.

Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, Miranda-Carboni GA, Krum SA.

J Bone Miner Res. 2013 Feb;28(2):283-90. doi: 10.1002/jbmr.1747.

7.

IFN-γ directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions.

Kohara H, Kitaura H, Fujimura Y, Yoshimatsu M, Morita Y, Eguchi T, Masuyama R, Yoshida N.

Immunol Lett. 2011 Jun 30;137(1-2):53-61. doi: 10.1016/j.imlet.2011.02.017. Epub 2011 Feb 19.

PMID:
21338623
8.

Roles of Wnt signals in bone resorption during physiological and pathological states.

Maeda K, Takahashi N, Kobayashi Y.

J Mol Med (Berl). 2013 Jan;91(1):15-23. doi: 10.1007/s00109-012-0974-0. Epub 2012 Oct 31. Review.

PMID:
23111637
9.
10.

Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.

Baum R, Gravallese EM.

Clin Rev Allergy Immunol. 2016 Aug;51(1):1-15. doi: 10.1007/s12016-015-8515-6. Review.

11.

The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.

Yang Y, Blair HC, Shapiro IM, Wang B.

J Biol Chem. 2015 Jul 3;290(27):16918-28. doi: 10.1074/jbc.M115.663963. Epub 2015 May 15.

12.

Maintenance of Bone Homeostasis by DLL1-Mediated Notch Signaling.

Muguruma Y, Hozumi K, Warita H, Yahata T, Uno T, Ito M, Ando K.

J Cell Physiol. 2017 Sep;232(9):2569-2580. doi: 10.1002/jcp.25647. Epub 2017 Mar 31.

13.

Deficiency of osteoblastic Arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of ER calcium homeostasis and induction of ER stress-mediated apoptosis.

Wu Y, Yang M, Fan J, Peng Y, Deng L, Ding Y, Yang R, Zhou J, Miao D, Fu Q.

Cell Death Dis. 2014 Oct 16;5:e1464. doi: 10.1038/cddis.2014.427.

14.

Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development.

Mukherjee A, Rotwein P.

Mol Cell Biol. 2012 Jan;32(2):490-500. doi: 10.1128/MCB.06361-11. Epub 2011 Nov 7.

15.

Lysophosphatidic acid: a potential mediator of osteoblast-osteoclast signaling in bone.

Sims SM, Panupinthu N, Lapierre DM, Pereverzev A, Dixon SJ.

Biochim Biophys Acta. 2013 Jan;1831(1):109-16. doi: 10.1016/j.bbalip.2012.08.001. Epub 2012 Aug 7. Review.

PMID:
22892679
16.

Fas/S1P1 crosstalk via NF-κB activation in osteoclasts controls subchondral bone remodeling in murine TMJ arthritis.

Hutami IR, Izawa T, Mino-Oka A, Shinohara T, Mori H, Iwasa A, Tanaka E.

Biochem Biophys Res Commun. 2017 Sep 2;490(4):1274-1281. doi: 10.1016/j.bbrc.2017.07.006. Epub 2017 Jul 4.

PMID:
28687489
17.

E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment.

Yang T, Grafe I, Bae Y, Chen S, Chen Y, Bertin TK, Jiang MM, Ambrose CG, Lee B.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7336-41. doi: 10.1073/pnas.1219748110. Epub 2013 Apr 15.

18.

Involvement of receptor-interacting protein 140 in estrogen-mediated osteoclasts differentiation, apoptosis, and bone resorption.

Piao H, Chu X, Lv W, Zhao Y.

J Physiol Sci. 2017 Jan;67(1):141-150. Epub 2016 Mar 26.

PMID:
27016936
19.

Transgenic overexpression of tartrate-resistant acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density.

Gradin P, Hollberg K, Cassady AI, Lång P, Andersson G.

Cells Tissues Organs. 2012;196(1):68-81. doi: 10.1159/000330806. Epub 2012 Jan 12.

PMID:
22248481
20.

The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.

Idris AI, Landao-Bassonga E, Ralston SH.

Bone. 2010 Apr;46(4):1089-99. doi: 10.1016/j.bone.2010.01.368. Epub 2010 Jan 22.

PMID:
20096813

Supplemental Content

Support Center